Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC

Prostate cancer (PCa) remains the most diagnosed non-skin cancer amongst the American male population. Treatment for localized prostate cancer consists of androgen deprivation therapies (ADTs), which typically inhibit androgen production and the androgen receptor (AR). Though initially effective, a...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Ralph E., Bannister, Maxwell, Day, Abderrahman, Bergom, Hannah E., Tan, Victor M., Hwang, Justin, Dang Nguyen, Hai, Drake, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348659/
https://www.ncbi.nlm.nih.gov/pubmed/37456235
http://dx.doi.org/10.3389/fonc.2023.1210487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348659/
https://www.ncbi.nlm.nih.gov/pubmed/37456235
http://dx.doi.org/10.3389/fonc.2023.1210487

Ejemplares similares